# Dated GBP listing sample — source-reviewed 14 September 2026

**142 supported listing observations across 12 suppliers. This is a prepared local packet, not a live website update. No press or supplier outreach occurred.**

## What the review actually established

| Scope | Result |
|---|---:|
| Original frozen GB-coded records with a recorded outcome | 295 / 295 |
| Original-cohort observations included | 139 |
| Additional UK-facing candidates considered separately | 7 |
| Additional UK-facing observations included | 3 |
| Total included observations | 142 |
| Total excluded original and additional candidates | 160 |
| Candidate observations rejected at independent content review | 10 |
| Previously included observations removed from the earlier packet | 2 |
| Price/nominal-quantity differences from the stored snapshot among retained original observations | 0 |

**This packet supersedes the earlier 17-observation packet for local use.** The deeper review excluded 2 previously included records because of conflicting own-product pack/chemical specifications. Other new exclusions concerned contradictory own-product chemical references. No guessed corrections were applied. Original captures and earlier artifacts were preserved.

The original cohort snapshot is dated **2026-09-14T15:52:57.390Z**. Included source captures range from **2026-09-14T16:54:56.889060+00:00** to **2026-09-14T18:13:32.268948+00:00**. Availability and prices are dated supplier claims, not live promises.

## New flagship coverage — not verification of the old blocked listings

| Supplier-labelled product | Supplier | Nominal mg | Displayed GBP price | Tax basis |
|---|---|---:|---:|---|
| retatrutide | Astra Labs | 10 | £59.99 | unknown |
| tirzepatide | Astra Labs | 10 | £44.99 | unknown |
| semaglutide | MyPeptides | 5 | £99.99 | unknown |

These are named-product observations only. The retatrutide record retains conflicting SKU metadata. The semaglutide record retains a supplier marketing/certificate-panel purity discrepancy, conditional tax wording and shipping uncertainty. No assay, exact-batch, safety, legality, medical-use, fulfilment or supplier-quality assertion is adopted. Full row caveats and source URLs are in the CSV.

## Files

- `reviewed-prices.csv`: every included source observation, exact-ratio numerator/denominator, displayed price, nominal quantity, tax flag, source time, geography basis and full caveats. Public references are for this packet only.
- `excluded-observations.csv`: all excluded original/additional records, source-stage outcome and independent-review reason where applicable. A blocked/unattempted case is not a successfully checked price.
- `coverage.csv`: original and additional counts kept separate by catalog label. No price averages, medians, minima or market-size estimates.
- `source-value-differences.csv`: differences from the unverified stored snapshot among included original records. It has 0 data rows; it is not a historical trend or a record of production edits.
- `historical-rounding-decisions.csv`: retained reconciliation of earlier database-snapshot rounding; not current source observations and not a live application change.
- `charts/`: eight original figures (coverage plus seven selected product-label tables), each as SVG, PNG and PDF. Other included products remain in the full CSV; the seven figures are not the whole sample.
- `METHODOLOGY.md`: eligibility, uncertainty, arithmetic, sampling and commercial disclosure.
- `SHA256SUMS.txt`: checksum manifest for the public members other than the manifest itself.

## Status and boundaries

All original records have an outcome; not every source was freshly retrieved or successfully accessible. Some known host blocks were retained without repeated requests. This is a purposive, access-dependent sample, **not complete UK-market coverage**. GB database codes are not verified legal domicile. Added UK-facing sources are separately labelled first-party delivery/location claims.

No original database value or verification date was changed. Prior website-publication authorisation is separate from execution: deployment remains paused at its unresolved release safety/confirmation gate. No publication, Git merge or external outreach was performed by this source-review task.

Keep the full methodology, row caveats and CSV beside any reused figure. No third-party HTML, product photos, COAs, reviews, logos, credentials or private source identifiers are distributed. No new blanket reuse licence is asserted.